Therapeutic and Prognostic Implications of Immune-Related Adverse Events in Advanced Non-Small-Cell Lung Cancer

INTRODUCTION: PD-(L)1 inhibitors have improved prognosis of non-small-cell lung cancer (NSCLC), but can also cause immune-related adverse events (irAEs) that complicate management. METHODS: We analyzed NSCLC patients receiving PD-(L)1 inhibitors from 2012 to 2020 in a German academic center. RESULTS...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Daniello, Lea, Elshiaty, Mariam, Bozorgmehr, Farastuk, Kuon, Jonas, Kazdal, Daniel, Schindler, Hannah, Shah, Rajiv, Volckmar, Anna-Lena, Lusky, Fabienne, Diekmann, Leonore, Liersch, Stephan, Faehling, Martin, Muley, Thomas, Kriegsmann, Mark, Benesova, Karolina, Stenzinger, Albrecht, Thomas, Michael, Christopoulos, Petros
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8277237/
https://ncbi.nlm.nih.gov/pubmed/34268127
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.703893
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados